These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8536519)

  • 1. Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy.
    Maruyama S; Hirayama C; Abe J; Tanaka J; Matsui K
    Dig Dis Sci; 1995 Dec; 40(12):2602-7. PubMed ID: 8536519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe chronic active hepatitis induced by UFTR containing tegafur and uracil.
    Kobayashi F; Ikeda T; Sakamoto N; Kurosaki M; Tozuka S; Sakamoto S; Fukuma T; Marumo F; Sato C
    Dig Dis Sci; 1995 Nov; 40(11):2434-7. PubMed ID: 7587827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
    Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
    Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary report of adjuvant chemo-endocrine therapy for breast cancer].
    Kitamura M; Tominaga T; Hayashi K; Takahashi I; Kosaki G
    Gan To Kagaku Ryoho; 1985 Jan; 12(1):111-7. PubMed ID: 3917652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
    Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic liver failure induced by long-term administration of tegafur: a case report.
    Matsumoto M; Nakao K; Matsumoto H; Iwata K; Ohta Y; Kanai K; Takahashi K; Akima M
    Hepatogastroenterology; 1998; 45(24):2372-5. PubMed ID: 9951926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined chemoendocrine treatment with tegafur and tamoxifen for advanced renal cell carcinoma.
    Wada T; Nishiyama K; Maeda M; Hara S; Tanaka N; Yasutomi M; Kurita T
    Anticancer Res; 1995; 15(4):1581-4. PubMed ID: 7654050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen.
    Vorgias G; Koukouras D; Tzoracoeleftherakis E; Paleogianni V; Androulakis J
    Anticancer Res; 2000; 20(5C):3849-54. PubMed ID: 11268466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
    Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
    J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
    Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
    J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
    Gelber RD; Cole BF; Goldhirsch A; Rose C; Fisher B; Osborne CK; Boccardo F; Gray R; Gordon NH; Bengtsson NO; Sevelda P
    Lancet; 1996 Apr; 347(9008):1066-71. PubMed ID: 8602056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy].
    Yasumura T; Oka T; Honjo H; Okada H
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2947-52. PubMed ID: 3140733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Capsule instead of infusion--new oral chemotherapy option].
    Köhne CH
    Krankenpfl J; 2002; 40(1-2):42-3. PubMed ID: 12035417
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
    Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.